

## EBITDA breakeven achieved on record sales

1<sup>st</sup> May 2018

Despite the apparent new air of 'entente cordiale' between North and South Korea, the world is still a dangerous place. What with alleged Russian state-involvement in the Salisbury nerve agent attacks, Syria's use of chemical weapons, ISIS' ongoing war against the West and the increasing threats posed by organised crime.

Indeed recently Turkish police, only after acting on a tip-off, managed to thwart a potentially heinous plan to sell 1.4kg of radioactive material (worth £49m) on the black market. Which is why the US Department of Defense (DoD) has committed to develop an early warning system for the detection of 'dirty bombs'.


Here Kromek has already shipped >10,000 D3Ss to the DoD - and in March won another \$1.6m contract to further enhance its state-of-the-art technology. The hope being ultimately to roll-out the device across 20+ US cities (each worth \$10m+), along with securing similar orders in other geographies (eg Europe).

### No change to our forecasts or 37p/share valuation

Encouragingly too, **the company is hitting its numbers**. Saying this morning that trading for the 12 months ended April 2018, had been "**in line with expectations**" - achieving "**EBITDA breakeven**" (Act -£311k H1 vs ED £300k H2) on top of positive revenue growth (ED £12.5m; Act £4.8m H1 vs ED £7.7m H2).

What's more, Kromek continues to "**gain traction**" across "**all its business segments**" - and expects further growth in FY19. As such **we make no change either to our numbers or 37p/share valuation**. Albeit we note that at 22p, the stock trades on a modest 3.6x FY19 EV/sales multiple vs 5.2x peers, despite its **superior growth trajectory** (see below).

### Current year (CY) EV/sales multiple




Source: Equity Development. Prices as at 30<sup>th</sup> April 2018 – arithmetic average

### Company Data

EPIC	AIM:KMK
Price (last close)	22p
52 week Hi/Lo	36p/20p
Market cap	£53m
ED value / share	37p

### Share Price, p



Source: WebFG

### Description

Kromek is pioneering digital colour imaging for x- and gamma rays, using cadmium zinc telluride crystals. Key markets include medical imaging, homeland security and nuclear detection.

Headquartered in Sedgefield (UK), Kromek has c.109 employees, of which approx. 88 are in R&D, with a 3 further sites in California, Pennsylvania and Germany. The firm has filed/registered >270 patents.

Having invested in its facilities, the company is able to manufacture >30k D3S' per year (re dirty bomb detection).

**Next news:** Prelims in July 2018


### Paul Hill (Analyst)

0207 065 2690  
[paul.hill@equitydevelopment.co.uk](mailto:paul.hill@equitydevelopment.co.uk)

### Andy Edmond

0207 065 2691  
[andy@equitydevelopment.co.uk](mailto:andy@equitydevelopment.co.uk)

### CY sales growth



Source: Equity Development

### Key risks

- Kromek is at a relatively early stage of its commercial development, with no absolute certainty that anticipated revenues or growth can be achieved.
- Orders tend to be lumpy in nature, and therefore by their nature difficult to forecast.
- The adoption of new break-through technology can take longer and cost more than originally thought.
- The company is executing on many fronts, and therefore it is important there is sufficient management resource to facilitate the growth.
- Scaling up production and aftermarket support to satisfy substantially higher volumes could cause teething problems.
- Protection of intellectual property, especially from patent challenges.
- Competitive pressures - albeit given Kromek's leading position in CZT, then this looks a less immediate threat.
- Customer concentration with one client representing 33% of FY17 sales.
- Regulatory changes which may impact the introduction of CZT based products.



## Head of Corporate

**Gilbert Ellacombe**

Direct: 0207 065 2698

Tel: 0207 065 2690

[gilbert@equitydevelopment.co.uk](mailto:gilbert@equitydevelopment.co.uk)

## Investor Access

**Hannah Crowe**

Direct: 0207 065 2692

Tel: 0207 065 2690

[hannah@equitydevelopment.co.uk](mailto:hannah@equitydevelopment.co.uk)

### **Equity Development Limited is regulated by the Financial Conduct Authority**

Equity Development Limited ('ED') is retained to act as financial adviser for various clients, some or all of whom may now or in the future have an interest in the contents of this document and/or in the Company. In the preparation of this report ED has taken professional efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee as to the accuracy or completeness of the information or opinions contained herein.

The research in this document has been produced in accordance with COBS 12.3 as Non-Independent Research and is a marketing communication. This document is not directed at, may not be suitable for and should not be relied on by anyone who is not an investment professional including retail clients. It does not constitute a personal investment recommendation and recipients must satisfy themselves that any dealing is appropriate in the light of their own understanding, appraisal of risk and reward, objectives, experience, and financial and operational resources. Research on its client companies produced and distributed by ED is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is deemed to be 'non-independent research' but is 'objective' in that the authors are stating their own opinions. This report has not been produced under legal requirements designed for independent research.

ED may in the future provide, or may have in the past provided, investment banking services to its client companies. For ED's employees and consultants there are rules to prevent dealing in the shares of client companies whilst notes are being prepared, or immediately after the note's release. Publication is achieved by a new note being freely available from the ED website. ED's engagement with corporate clients is governed by the laws of England & Wales. In the UK, companies quoted on AIM are subject to lighter due diligence than shares quoted on the main market and are therefore more likely to carry a higher degree of risk than main market companies.

This report is being provided to relevant persons by ED to provide background information about Kromek Group. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. Self-certification by investors can be completed free of charge at [www.fisma.org](http://www.fisma.org)

More information is available on our website

[www.equitydevelopment.co.uk](http://www.equitydevelopment.co.uk)

Equity Development, 15 Eldon Street, London, EC2M 7LD. Contact: [info@equitydevelopment.co.uk](mailto:info@equitydevelopment.co.uk) 0207 065 2690